Disordered coagulation contributes to death in sepsis and lacks effective treatments. Existing markers of disseminated intravascular coagulation (DIC) reflect its sequelae rather than its causes, delaying diagnosis and treatment. Here we show that disruption of the endothelial Tie2 axis is a sentinel event in septic DIC. Proteomics in septic DIC patients revealed a network involving inflammation and coagulation with the Tie2 antagonist, angiopoietin-2 (Angpt-2), occupying a central node. Angpt-2 was strongly associated with traditional DIC markers including platelet counts, yet more accurately predicted mortality in 2 large independent cohorts (combined $N = 1,077$). In endotoxemic mice, reduced Tie2 signaling preceded signs of overt DIC. During this early phase, intravital imaging of microvascular injury revealed excessive fibrin accumulation, a pattern remarkably mimicked by Tie2 deficiency even without inflammation. Conversely, Tie2 activation normalized prothrombotic responses by inhibiting endothelial tissue factor and phosphatidylserine exposure. Critically, Tie2 activation had no adverse effects on bleeding. These results mechanistically implicate Tie2 signaling as a central regulator of microvascular thrombus formation in septic DIC and indicate that circulating markers of the Tie2 axis could facilitate earlier diagnosis. Finally, interventions targeting Tie2 may normalize coagulation in inflammatory states while averting the bleeding risks of current DIC therapies.
Tie2 protects the vasculature against thrombus formation in systemic inflammation

Sarah J. Higgins,1,2 Karen De Ceunynck,3 John A. Kellum,4 Xiuying Chen,1,2 Xuesong Gu,3 Sharjeel A. Chaudhry,3 Sol Schulman,3 Towia A. Libermann,5 Shulin Lu,6 Nathan I. Shapiro,4 David C. Christiani,7 Robert Flaumenhaft,3 and Samir M. Parikh1,2

1Division of Nephrology and Department of Medicine, 2Center for Vascular Biology Research, and 3Division of Hemostasis and Thrombosis and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA. 4Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 5Bioinformatics, and Systems Biology Center, Department of Medicine, Division of Interdisciplinary Medicine and Biotechnology, and 6Department of Emergency Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA. 7Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School and the Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA.

Disordered coagulation contributes to death in sepsis and lacks effective treatments. Existing markers of disseminated intravascular coagulation (DIC) reflect its sequelae rather than its causes, delaying diagnosis and treatment. Here we show that disruption of the endothelial Tie2 axis is a sentinel event in septic DIC. Proteomics in septic DIC patients revealed a network involving inflammation and coagulation with the Tie2 antagonist, angiopoietin-2 (Angpt-2), occupying a central node. Angpt-2 was strongly associated with traditional DIC markers including platelet counts, yet more accurately predicted mortality in 2 large independent cohorts (combined N = 1,077). In endotoxemic mice, reduced Tie2 signaling preceded signs of overt DIC. During this early phase, intravital imaging of microvascular injury revealed excessive fibrin accumulation, a pattern remarkably mimicked by Tie2 deficiency even without inflammation. Conversely, Tie2 activation normalized prothrombotic responses by inhibiting endothelial tissue factor and phosphatidylserine exposure. Critically, Tie2 activation had no adverse effects on bleeding. These results mechanistically implicate Tie2 signaling as a central regulator of microvascular thrombus formation in septic DIC and indicate that circulating markers of the Tie2 axis could facilitate earlier diagnosis. Finally, interventions targeting Tie2 may normalize coagulation in inflammatory states while averting the bleeding risks of current DIC therapies.

Introduction

Death from severe infection is a global health threat (1–3). Of all acute illnesses, the public health burden of sepsis may be the most pressing — patients spend longer in intensive care units (ICUs) and hospitals and more commonly suffer long-term health impairments compared with all other admission diagnoses (1). Severe sepsis is frequently complicated by a distinct and lethal syndrome in which coagulation occurs indiscriminately throughout the circulation. Exuberant formation of microthrombi consumes platelets and circulating coagulation factors from the blood. Platelet dysfunction arises and inhibitors of coagulation are depleted. These complex changes often render the patient susceptible to bleeding (4–6).

Termed disseminated intravascular coagulation (DIC), this complication of sepsis is extraordinarily difficult to treat for several reasons. First, the microthrombi of DIC critically impair organ perfusion, thereby accelerating the multiorgan dysfunction that precedes death from sepsis. Second, by the time septic DIC is recognized, individual patients may simultaneously exhibit manifestations of tissue ischemia from elevated microthrombi and spontaneous bleeding. Third, because the diagnosis of DIC is based on hematologic abnormalities that develop as a consequence rather than cause of excessive thrombus generation and breakdown — e.g., reduced platelets or elevated D-dimers (7) — clinical recognition of the pathophysiology underlying DIC may be delayed. Finally, the treatment of DIC is completely empirical. Platelets and coagulation factors are administered to treat excessive bleeding, and anticoagulants are given when thrombotic manifestations are dominant. As a result, treatment of DIC can itself inflict harm by triggering excess thrombus formation or bleeding. Improved understanding of the underlying mechanisms in septic DIC may therefore aid the development of new strategies to recognize and manage this complex syndrome.

Current models of DIC in sepsis have focused on interactions among platelets, leukocytes, and coagulation factors. Platelets can be activated in systemic inflammation either directly by leukocyte-derived cytokines and bacterial products (8, 9) or indirectly — e.g., tissue factor (TF) expression resulting in the generation of thrombin, which is a potent platelet agonist (4). Targeting upstream cytokines or bacterial products in sepsis has thus far been unsuccessful despite numerous attempts with potent biology (refs. 10–12 and summarized in 13). Impairment of endogenous
The endothelium provides a critical surface for activation of coagulation and recruitment of platelets (17), and homeostatic endothelial signaling pathways are markedly altered in human sepsis (18). Whether this disruption contributes directly to abnormal coagulation in sepsis is an open question. Similarly, it is unknown whether normalizing endothelial signaling would reverse the prothrombotic influence of systemic infection.

Anticoagulation systems can lead to dysfunctional coagulation and promote microthrombi. Yet, pivotal late-stage clinical trials to restore physiological anticoagulants that become diminished in sepsis, such as antithrombin III, TF pathway inhibitor, and protein C, have not shown benefit, and instead may even increase adverse bleeding events (14–16).

In contrast, understanding of how the endothelium, which undergoes profound changes in response to systemic inflammation, contributes to septic DIC remains poorly developed. The endothelium provides a critical surface for activation of coagulation and recruitment of platelets (17), and homeostatic endothelial signaling pathways are markedly altered in human sepsis (18). Whether this disruption contributes directly to abnormal coagulation in sepsis is an open question. Similarly, it is unknown whether normalizing endothelial signaling would reverse the prothrombotic influence of systemic infection.

Figure 1. Discovery proteomics in septic DIC implicate endothelium and Angpt-2. (A) Heatmap representation of SOMAScan plasma analytes in severe sepsis with DIC (n = 7) and sepsis (n = 7). Color scale indicates relative expression. (B) Volcano plot showing analytes that were increased or decreased in sepsis DIC compared with sepsis without DIC (non-DIC) with P values less than 0.05 indicated in red. (C) STRING analysis and visualization of high-confidence interaction clusters (k-means = 9 clusters indicated by node color) formed by plasma proteins and labeled on related functional categories. Solid line represents within-cluster, dashed gray line represents between-cluster interactions.
Described below, we undertook an unbiased proteomics approach in patients with septic DIC in order to identify causal factors. Whereas the clinical criteria for DIC relate solely to platelets and coagulation parameters, network analysis of the proteomics strongly implicated the endothelium, including alterations in the endothelial regulatory angiopoietin-1 (Angpt-1)/Tie2 signaling axis. Tie2 is a receptor that is highly enriched in the endothelium and actively signals vascular quiescence (19–22). Tie2 is stimulated by Angpt-1, a protein secreted by periendothelial cells and platelets. In the context of inflammation, a paralog of Angpt-1 called Angpt-2 competitively inhibits Tie2 (23–32). While several groups have shown that the Angpt/Tie2 pathway becomes dysregulated in human sepsis (reviewed in ref. 33), it is not known whether disrupted Angpt/Tie2 signaling in the endothelium exerts a direct mechanistic effect on the thrombotic complications. The present studies suggest that Tie2 signaling disruption is an early and pathogenic event in septic DIC, driving a fundamental phenotypic switch in the endothelium that promotes excessive fibrin deposition. The results identify a direct molecular mechanism by which the inflamed endothelium precipitates thrombus formation and propose new ways to inform the recognition and treatment of DIC in septic patients.

**Results**

**Discovery proteomics in septic DIC implicate endothelium and Angpt-2.** To identify novel regulators of coagulation in sepsis, we performed unbiased proteomic analysis on plasma from matched patients in the ICU with sepsis (Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/JCI97488DS1) characterized as non-DIC or DIC. Protein-specific, slow-off-rate-modified DNA aptamers (SOMAmers) enabled simultaneous and sensitive detection of approximately 1,300 plasma proteins. Two hundred and two analytes were differentially expressed in septic patients with DIC versus septic non-DIC patients (P ≤ 0.05, Figure 1, A and B). These included both known markers of DIC — e.g., anticoagulant protein C, coagulation factor II (thrombin), coagulation factor XI — and potentially novel proteins. In order to elucidate candidate regulators among the top analytes, we conducted network and cluster analysis in STRING, a database of protein-protein interactions curated across major repositories of experimental results (34, 35). One hundred and seventy-three of the 202 hits in sepsis DIC (P value cutoff ≤ 0.05, Figure 1A) formed distinct interacting protein clusters that were highly enriched in pathways associated with coagulation, vascular function, complement, and endothelial inflammation (Figure 1C). Angpt-2 occupied a central node in this analysis linking vascular function, endothelial inflammation, and coagulation, and was itself highly increased in plasma of septic patients with DIC compared with those without (Figure 2A, 4.98-fold enhancement, P = 0.003). A fall in the ratio of Angpt-1/Angpt-2 is considered a peripheral indicator of reduced Tie2 signaling and is associated with adverse manifestations of diverse severe infections (36–38). We analyzed SOMAScan Angpt-1 levels (Figure 2B) and confirmed this ratio was significantly lower in patients with DIC compared with non-DIC sepsis (Figure 2C). Angpt-2, Angpt-1, and the Angpt-1/2 ratio detected by SOMAScan were confirmed by commercial ELISA (Figure 2D and Supplemental Figure 1, A and B) with a high degree of agreement between the 2 methods for Angpt-2 (r² = 0.85, P < 0.0001; Figure 2E) and Angpt-1 (r² = 0.63, P = 0.002, Supplemental Figure 1C). Plasma Angpt-2 discriminated between DIC and non-DIC septic patients within the selected cohort (area under the receiver operating characteristic [ROC] curve = 0.88, P = 0.007, Figure 2F). Using clinical laboratory tests, we found that Angpt-2 was inversely correlated with parameters that decline in DIC, including platelet count (r² = 0.37, Figure 2G) and fibrinogen (r² = 0.81, Figure 2H), the plasma glycoprotein cleaved by thrombin in the coagulation cascade to form fibrin in clots.

To validate the performance of Angpt-2 in differentiating patients with DIC risk factors in an independent cohort (n = 221; see ref. 27), a cutoff value (10 ng/ml) was derived from the ROC curve (Figure 2F) and Youden index analysis (0.6, sensitivity, 85.7; specificity, 71.43). Patients in the high Angpt-2 group (>10 ng/ml)
Table 1. DIC parameters based on angiopoietin-2 levels

<table>
<thead>
<tr>
<th>DIC parameter</th>
<th>Angpt-2 &lt; 10 ng/ml</th>
<th>Angpt-2 ≥ 10 ng/ml</th>
<th>P</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelet count (k/μl)</td>
<td>142.1 (91.2)</td>
<td>249.4 (168.0)</td>
<td>&lt;0.0001</td>
<td>204</td>
</tr>
<tr>
<td>PT (INR)</td>
<td>3.03 (2.78)</td>
<td>1.66 (1.26)</td>
<td>&lt;0.0001</td>
<td>153</td>
</tr>
<tr>
<td>D-dimer (ng/ml)</td>
<td>6.245 (2.645)</td>
<td>1.879 (1.540)</td>
<td>0.0094</td>
<td>11</td>
</tr>
</tbody>
</table>
threshold and increasing concentrations of classical platelet agonists (Supplemental Figure 4). Furthermore, the exuberant thrombus formation during early endotoxemia was not attributable to changes in platelet activation, as assessed by platelet-factor 4 levels (Figure 4H).

Together, these results implicate an early and coordinated response of the endothelium to systemic inflammation that promotes thrombus formation before the onset of overt DIC.

**Tie2 deficiency alone recapitulates sepsis-associated thrombotic response.** As dysregulation of the Angpt/Tie2 pathway was associated with a prothrombotic state, we next studied microvascular thrombus formation in Tie2+/− mice. Heterozygous mice are indistinguishable from wild-type (WT) littermates at baseline, but exhibit increased susceptibility to inflammation and infections (19, 37, 45). Unexpectedly, partial Tie2 deficiency alone was sufficient to enhance fibrin deposition independent of LPS (Figure 5, A-E). The enhanced fibrin deposition in Tie2+/− mice compared with Tie2+/+ mice was not attributable to differences in platelet accumulation at the injury site (Figure 5, B and C), circulating platelet count (mean platelets/μl × 10^9 ± SD: 6.9 ± 0.7, n = 8 for Tie2+/+ vs. 6.7 ± 0.8, n = 7 for Tie2+/−), or ex vivo coagulation parameters (mean PT [seconds] ± SD: 11.57 ± 0.94, n = 7 for Tie2+/+ vs. 11.14 ± 0.52, n = 15 for Tie2+/− and mean activated partial thromboplastin time [aPTT, in seconds] ± SD: 33.91 ± 5.34, n = 7 for Tie2+/+ vs. 31.77 ± 3.83, n = 13 for Tie2+/−) or baseline differences in circulating white cells (Supplemental Figure 5). However, when challenged with LPS, Tie2+/− mice exhibited an exacerbated response and progression to DIC-type complications, with increased PT and elevated thrombin generation, as indicated by increased TAT compared with Tie2+/+ controls (Supplemental Figure 6), supporting the suggestion that Tie2 is important for regulation of thrombus formation on the vessel wall and loss of Tie2 function may have detrimental effects on excessive thrombosis.

To evaluate the role for platelets within this context, we returned to the endotoxemia model in WT C57BL/6 mice in which we applied the platelet glycoprotein αIIbβ3 inhibitor eptifibatide to inhibit platelet aggregation at the injury site. Despite virtual absence of platelet accumulation (Figure 5, F–H), fibrin accumulation was increased in endotoxemic mice (Figure 5F, I and J), analogous to both the endotoxemia model without eptifibatide (Figure 4, A, D, and E) and the nonendotoxemic Tie2−/− mice (Figure 5, A, D, and E). These results suggest that the Tie2 signaling deficiency arising in sepsis is sufficient to provoke fibrin deposition on the vessel wall.

**Tie2 activation suppresses prothrombotic actions of LPS on the endothelium.** To evaluate the role of the endothelium and Tie2 directly, we applied LPS and human plasma to primary human endothelial cells, then monitored the generation of factor Xa (FXa) and thrombin. The sequential action of these serine proteases converts fibrinogen to fibrin. LPS enhanced FXa and thrombin generation on the cultured endothelium; these effects were significantly attenuated by Angpt-1 application (Figure 6, A-D),
with a more pronounced effect on thrombin generation even when Angpt-1 was applied to cells 2 hours after LPS exposure (Supplemental Figure 7).

Since endothelial TF exposure was necessary for LPS-dependent FXα and thrombin generation (Figure 6, B and D), we next determined the effect of Angpt-1 on endothelial TF. Studies using a TF-specific antibody (Supplemental Figures 8, A and B) demonstrated that preapplication of Angpt-1 reduced both the level and surface exposure of TF induced by LPS (Figure 6, E–G), suggesting that constitutive Tie2 activation may lead to TF downregulation in quiescent endothelial cells. When we forced TF expression, Angpt-1’s ability to attenuate FXα generation was abrogated (Supplemental Figure 8, C and D), supporting a protective role for the Angpt-1/Tie2 pathway, in part, by regulating TF expression. Endothelial PI3K and Akt are activated by Tie2, and in nonendothelial cells, this signaling cascade suppresses TF (46, 47). Using Tie2 RNAi (Supplemental Figure 9, A and B) and a pharmacological inhibitor of PI3K to block Akt phosphorylation, we confirmed that Angpt-1 required intact Tie2 expression and downstream PI3K/Akt signaling in order to counteract LPS-induced FXα generation (Supplemental Figure 9, C–E).

To explain the effect of Angpt-1 on thrombin generation delivered after LPS exposure, we next found that LPS-treated HUVECs mimic the externalization of the anionic phospholipid phosphatidylserine (PtdSer) observed on activated platelets (48), with LPS-dependent FXα and thrombin generation reduced by lactadherin, a stereospecific blocker of PtdSer (Figure 6, B and D). LPS increased the population of FITC-labeled annexin V-positive HUVECs compared with controls, indicative of increased PtdSer exposure, and Angpt-1 effectively counteracted this effect (Figure 6, H and I). Cumulatively, these results demonstrate that Angpt-1 counteracts the LPS-dependent conversion of the endothelial surface to a procoagulant state.
Tie2 activation normalizes the septic thrombotic response to injury without increasing bleeding risk. We next administered Angpt-1 via gene transfer in endotoxemic mice (Supplemental Figure 10). Angpt-1 normalized fibrin deposition at sites of vascular injury in LPS-exposed mice to levels observed in control-virus-treated mice (Figure 7, A, D, and E), with a trend towards lower platelet accumulation (Figure 7, A–C). This was not attributable to baseline differences in coagulation parameters or the potential to form thrombi in mice receiving adenoviral vector injections (Supplemental Figure 11). The ability of Angpt-1 delivery to normalize the thrombotic response was confirmed in an independent model of polymicrobial infection (cecal ligation and puncture, CLP; Supplemental Figure 12), complementing the findings from endotoxemia that normalization of Tie2 signaling may counteract septic DIC. Despite being stored and released by activated platelets (Supplemental Figure 13, A and B), increased systemic Angpt-1 levels did not affect platelet aggregation ex vivo in the absence of vessel wall interactions (Supplemental Figure 13, C and D). Importantly, Angpt-1 did not increase the risk of bleeding complications, a problem limiting the use of current clinical antithrombotic therapies for
DIC. In fact, Angpt-1 treatment restored normal bleeding time and lowered the number of rebleeding events in endotoxemic mice (Figure 7, F and G) without a direct effect on total platelet count (Supplemental Figure 13E).

In agreement with our in vitro observations, delivery of Angpt-1 reduced spontaneous in situ fibrin accumulation triggered by LPS (Figure 7, H and I). Angpt-1 also reduced thrombin generation in response to LPS compared with generation observed in control-vector-treated endotoxemic mice, indicated by measuring the fold change in TAT complex levels (Figure 7J). Furthermore, Angpt-1 significantly reduced Angpt-2 expression (Figure 7, L and M), heightened levels of which were associated with DIC in our human sepsis cohorts (Figure 1 and Tables 1 and 2), via maintenance of Tie2 activation (Figure 7M). These results extend the cellular findings of Figure 6 to show that Angpt-1 normalizes thrombus formation in vivo during systemic inflammation without increasing bleeding risk.

**Discussion**

The present work demonstrates a pivotal and specific role for endothelial homeostasis signaled through Tie2 to combat disordered thrombus formation arising from systemic inflammation. Whereas DIC research has traditionally focused on platelets, coagulation factors, and leukocytes, a role for the endothelium, and more specifically the Angpt/Tie2 pathway, was suggested by unbiased discovery in human subjects that demonstrated a coordinated activation of this understudied single cell layer in septic DIC. These results were sufficiently robust to be reaffirmed in more than 1,000 additional patients from 2 independent cohorts, demonstrating that high
Angpt-2, released by activated endothelial cells, is not only linked to markers of DIC, but also an accurate determinant of patient outcome. Studies in a mouse model of sepsis-induced DIC coupled with cellular experiments showed a mechanistic involvement of the endothelial Tie2 pathway in regulating thrombus formation.

These results support the concept that the endothelium is a pivotal contributor to inflammatory thrombus formation. Endothelial activation, including dysfunction of the Tie2 axis, temporally preceded the measurable involvement of platelets and coagulation factors. Moreover, this endothelial dysfunction could be targeted in a highly precise molecular fashion, using an adenoviral construct expressing the vascular protective protein Angpt-1 to maintain Tie2 signaling, both to normalize the initial fibrin deposition response of early sepsis, without adversely interfering with hemostasis, and to abrogate the elevated thrombin levels in DIC. Antecedent involvement of the endothelium and phenotypic reversal with an endothelium-targeted intervention therefore strongly implicate the endothelium in the pathogenesis of septic DIC.

Figure 7. Tie2 activation normalizes the septic thrombotic response to injury without increasing bleeding risk. Representative binarized images of thrombus formation (A) following laser injury in mice injected with control adenovirus (CtlAdv) (top) or an adenovirus expressing Angpt-1 (AdAngpt-1) after LPS injection (1–3 hours) (platelets = red; fibrin = green). Scale bar: 10 μm. Median integrated platelet (B) and fibrin (D) fluorescence intensities and AUC (C and E) were calculated for individual thrombi, CtlAdv (n = 2; 33 thrombi), CtlAdv plus LPS (n = 3; 37 thrombi), AdAngpt-1 (n = 3; 38 thrombi), and Angpt-1 plus LPS (n = 3; 37 thrombi). (F) Time to bleeding cessation (seconds) in CtlAdv and AdAngpt-1 mice 3 hours after LPS challenge (n = 18 or 19 mice). (G) The number of re-bleeding events during 10-minute observation window stratified as follows: 0, 1–3, or 4 or more events. Representative immunoblot (H) and quantification (I) of fibrin in liver isolates relative to pan cadherin. (J) Relative change in TAT complex levels at 3 hours after LPS challenge in CtlAdv- and AdAngpt-1–treated mice. Angpt-2 levels in (K) plasma and (L) lungs of CtlAdv or AdAngpt-1 mice after LPS (n = 5 per group). *P < 0.05, **P < 0.01 by 1-way ANOVA. (M) Representative immunoblots of p-Tie2 (p-Tie2(Y992)) and total Tie2 levels in lung isolates.
An argument for the endothelium’s role in septic DIC is further strengthened by several additional lines of evidence. First, platelets are considered the primary surface for coagulation at sites of vascular injury. Nonetheless, our results indicate that the increased fibrin deposition at sites of injury associated with early sepsis occurs even when platelets are inhibited (Figure 5, F–J). Although this does not exclude a role for platelets in septic thrombin generation, the present results are consistent with previous in vivo studies showing that activated endothelial cells can support assembly of the prothrombinase complex required for thrombin and fibrin generation (17, 49). Second, while Tie2 signaling has long been known to decline in sepsis, here we found that genetically reduced Tie2 alone was sufficient to mimic the excessive fibrin deposition of sepsis (Figure 5, A–E). The small fraction of monocytes that express Tie2 are unlikely to account for this fibrin response (50); furthermore, Angpt-1 gene transfer did not significantly impact levels of red or white blood cells, including monocytes (Supplemental Figure 14). Third, the cellular studies directly identify endothelial inflammation as a sufficient provocation to catalyze fibrin formation. These experiments revealed that LPS upregulates parallel inducers of the coagulation cascade, TF and PtdSer, a finding that affirms and extends previous studies of the endothelium in vivo and in vitro (17, 49) and that Angpt-1 exerts actions to blunt this response. While our in vitro studies using HUVECs have limitations inherent to studies of coagulation on cultured cells, it is a well-established model (51–53). Finally, in endotoxemic mice, Angpt-1 gene transfer improved both the early prothrombotic response of systemic inflammation and the late fibrin accumulation, suggesting an action most consistent with a normalization effect. And unlike existing DIC therapies, this normalization was achieved without increasing bleeding events. Together, the results suggest that endothelial Tie2 disruption is necessary for endothelium-mediated thrombosis in early sepsis and that Tie2 activation is sufficient to ameliorate this process.

The striking normalization effect achieved by exogenous Angpt-1 on thrombus formation may unveil an adaptive endogenous process supported by platelets (54). Platelets may contain substantial amounts of Angpt-1 (55), so their aggregation at nascent thrombi may release Angpt-1 to restore endothelial homeostasis. In sepsis, platelet-derived Angpt-1 could also restore other aspects of endothelial quiescence such as barrier function and antiinflammation (56). The present results conversely suggest that the fall in circulating Angpt-1 during endotoxemia may contribute to DIC, raising questions about the major source(s) of Angpt-1 during health and its turnover in sepsis that will require further study.

The present results also advance an important contrast against vascular endothelial growth factor (VEGF). As major control pathways for the endothelium, both the Angpts and VEGF regulate angiogenesis, barrier function, and inflammation — Angpt-2 and VEGF both weaken the vascular barrier and promote inflammation, actions that Angpt-1 counteracts. Yet their deficiencies result in starkly divergent defects in clot formation. Our data show that Tie2 deficiency yielded fibrin-dominant lesions at sites of vascular injury, whereas VEGF deficiency is known to promote the platelet-rich thrombi found in thrombotic microangiopathy (TMA) (57–59). Since both injury-induced and spontaneous fibrin deposition during endotoxemia were attenuated by excess Angpt-1 (Figure 7, D and H) yet thrombocytopenia was not prevented by Angpt-1 (Supplemental Figure 13E), the results collectively suggest that the effects of sepsis on platelet abundance may not only be driven by consumption, but also additional mechanisms such as pulmonary sequestration and even blunted megakaryopoiesis (60–62). Regarding the status of the endothelium, just as certain forms of TMA are responsive to restored VEGF signaling (63), septic DIC may be similarly responsive to restored Tie2 signaling. With a ligand-independent activator of Tie2 and antibodies to inhibit Angpt-2 all in clinical development, there is significant translational potential for Tie2 stimulation (43, 64, 65). Therefore, the mechanisms underlying these phenotypic differences should be further investigated.

While the endothelium has long been considered a contributor to septic DIC, an easily measurable, mechanistic, and pharmacologically targetable response has been elusive. Therapeutic strategies such as Angpt-1 targeting the endothelium may reduce the risks of iatrogenic harm from the therapeutic overshoots associated with current empiric DIC treatments. Our results suggest that Tie2 stimulation after the onset of sepsis may still be beneficial against fibrin-rich clot formation (Supplemental Figure 7), in line with recent results demonstrating a survival benefit in septic mice even with delayed Tie2 stimulation (32). Application of Tie2 axis markers may aid the identification of individuals with pathomechanisms amenable to Tie2-stimulating therapies, as suggested by an earlier study of Angpt-2 in septic DIC (66) and augmented by the present investigation of more than 1,000 subjects. Considered together, these early human studies suggest the potential for diagnosing DIC risk by measuring its causal mechanisms rather than its consequences on platelet counts and other parameters. Beyond septic DIC, disordered coagulation and hemostasis occurs in many severe infections, ranging from Ebola virus disease to cerebral malaria. Clinical data and experimental models link disturbances in the Angpt/Tie2 pathway to several of these disease states (37, 38, 67–71), raising the possibility that defense of endothelial homeostasis can counteract prothrombotic mechanisms arising from diverse infections.

In summary, the present work demonstrates a pivotal and specific role for endothelial homeostasis signaled through Tie2 to combat disordered thrombus formation arising during systemic inflammation. These findings may open new avenues to study the role of the endothelium in diseases of abnormal coagulation, and also to develop new markers and therapies for individuals affected by septic DIC.

Methods

**Human samples and patient selection for SOMAscan.** Samples for SOMAscan analysis were collected from the Molecular Epidemiology of ARDS (MEARDS) prospective cohort study (ClinicalTrials.gov Identifier: NCT00006496), which recruited patients at the ICUs of Massachusetts General Hospital (MGH) and Beth Israel Deaconess Medical Center (BIDMC) between 1998 and 2014. Study population and procedures were described previously (19). For the purpose of the current study, sepsis and sepsis DIC groups were defined based on the International Society of Thrombosis and Hemostasis (ISTH) DIC Scoring system (72), determined by laboratory tests for the following parameters: low platelet count, prolonged clotting time, and increased D-dimer and/or decreased fibrinogen.
Proteomic analysis using slow-off-rate-modified aptamer SOMAScan platform. EDTA-plasma from 7 patients with sepsis and seven patients with sepsis DIC were analyzed using DNA-aptamer-based recognition on the SOMAScan platform (SomaLogic) at the BIDMC Genomics, Proteomics, Bioinformatics and Systems Biology Center. Samples were prepared and run using the SOMAScan Assay Kit for human plasma, L3k (catalog 900-00011), according to the standard protocols from SomaLogic, as described previously (73). Five pooled plasma controls and 1 no-protein buffer control were run in parallel with the samples. Median normalization and calibration of the data was performed according to the standard quality control protocols at SomaLogic. All samples passed the established quality control criteria. P values were determined by t test.

Network, clustering, and functional enrichment analysis. Volcano plot was generated using binary fold-change and -log, P value for plasma analytes measured by SomaScan. Proteins with significant differences in abundance between groups were selected based on a fold-change greater than 1.2 and P value of 0.05 or less and included in subsequent network analysis. The selected proteins were searched against the STRING database version 10.5 for protein-protein interactions and displayed as a functional network (35). Interactions were considered with a STRING confidence score of 0.7 or higher (high to highest confidence) culled from the “experimental” and “databases” categories. Nodes with no associations to other proteins in the network were removed. A k-means clustering algorithm was performed to identify densely connected regions (k-means = 9). Functional description of clusters was assigned based on a manual curated evaluation of enriched KEGG pathway, Gene Ontology (GO) terms, and PubMed literature search.

ELISA validation of SOMAScan. EDTA-plasma concentrations of Angpt-2 and Angpt-1 were measured by ELISA (R&D Systems), according to the manufacturer’s instructions.

Clinical validation of SOMAScan. A secondary analysis of patients who participated in 2 published studies was undertaken: (a) the Protocolized Care for Early Septic Shock (ProCESS) trial, a patient-level randomized, multicenter interventional trial of alternative resuscitation strategies in Emergency Department Sepsis (ClinicalTrials.gov Identifier: NCT00793442) (39); and (b) an IRB-approved prospective cohort study of 221 adult patients age 18 years and older presenting to the Emergency Department of BIDMC with suspected infection (27). Blood was collected upon enrollment, immediately centrifuged, and then stored at -80°C for subsequent analysis. PT, international normalized ratio (INR), aPTT, and platelet counts were measured using clinically available laboratory testing. D-dimers were measured using a latex agglutination assay (Diagnostica Stago). All assays were performed according to the manufacturer’s specifications. Ethics committee approval was received from participating sites, University of Pittsburgh and BIDMC Committee for Clinical Investigations.

Mice. C57BL/6J mice (male, 8–12 weeks old) were purchased from The Jackson Laboratory. Heterozygous Tie2 mice (Tie2ΔTie2) and littermate (Tie2ΔTie2) controls were generated on a CD1 background as described previously (45). Mice were anesthetized through intraperitoneal (i.p.) injection of a ketamine (125 mg/kg) and xylazine (12.5 mg/kg) mixture in sterile saline. For laser-injury thrombosis experiments, pentobarbital (5 mg/kg) was administered through a jugular vein cannula to maintain anesthesia. For retro-orbital blood collection, mice were sedated using isoflurane.

Endotoxemia model. Mice were administered LPS from E. coli serotype O111:B4 (Sigma-Aldrich; 10 mg/kg body weight) via i.p. injection. Disease severity was assessed using a 7-parameter scoring system for murine sepsis, as described previously (74).

Adenoviral gene transfer. Mice were injected with an adenovirus expressing human Angpt-1 (AdAngpt-1; 2 × 1010 viral particles, Qbiogene Inc.) or GFP (Ad-CMV-GFP, control; 2 × 1010 viral particles, Qbiogene Inc. and Vector Biosystems) via intravenous (i.v.) tail injection in saline 72 hours prior to saline or LPS administration (75). Levels of Angpt-1 in plasma were confirmed by DuoSet ELISA against human Angpt-1 (R&D Systems). Mice that were assigned to receive AdAngpt-1 but did not have elevated Angpt-1 levels (above the control adenovirus group) were excluded from analysis.

Platelet aggregation. Platelet-rich plasma (PRP) from citrated whole blood (3.2% sodium citrate) obtained by retro-orbital plexus puncture using glass capillaries was prepared by differential centrifugation with HEPES Tyrode buffer (20 mM HEPES, 134 mM NaCl, 0.34 mM NaH2PO4, 2.9 mM KCl, 12 mM NaHCO3, 1 mM MgCl2, 5 mM glucose; pH 7.3) as described previously (76). PRP was diluted to a final platelet count of 200,000 platelets per μl. Platelet aggregation was initiated using PAR4-agonist (AYPGKF; Sigma-Aldrich) or collagen (385, ChronoLog), at indicated concentrations, and measured using the ChronoLog 680 aggregometer. An agonist dose curve was run for each independent experiment to determine the lowest dose at which aggregation was obtained.

Endothelial and platelet activation markers. Levels of soluble E-selectin, soluble VCAM, serpin E1/PAI-1, and platelet factor 4 (PF4) were measured in plasma using ELISA kits (Quantikine and DuoSet Immunoassays, R&D Systems), according to the manufacturer’s protocols. VWF levels were measured using an in-house-developed ELISA as described previously (77). Angpt-2 and TAT were measured using mouse ELISA kits, as per the manufacturer’s protocol (Abcam).

Coagulation assays. PT (Neoplastin Cl Plus), aPTT, and D-dimer (Asserachrom D DI kit) were measured in plasma according to the manufacturer’s instructions (Diagnostica Stago Inc.). Hematological analysis of total blood count was performed using a Hemavet 850FS (Drew Scientific) for platelet, white blood cell (WBC), monocyte (MO), lymphocyte (LY) and red blood cell (RBC) counts, and hemoglobin (Hb) and hematocrit (HCT).

Laser-injury thrombosis model. Thrombus formation in response to laser injury was measured as described previously (49, 78). Briefly, cremaster arterioles and venules were injured using a MicroPoint Laser system (Photonics Instruments). Platelet and fibrin accumulation was measured by infusion of Dylight 647-labeled anti-platelet antibodies (CD42b; 0.1 mg/g body weight; Emfret Analytics) and Dylight 488-labeled (Thermo Fisher Scientific) anti-fibrin antibodies (59D8; 0.5 mg/g body weight) through a jugular vein catheter. Data acquisition was done prior and subsequent to laser injury in 2 channels (488/520 nm and 640/670 nm). Images were captured for 180 seconds at 0.5 frames/second using a CCD camera (Hamamatsu). Data were analyzed using Slidebook 6.0 (Intelligent Imaging Innovations). Data from 30 to 40 thrombi were used to determine the median value of the integrated fluorescence intensity to account for the variability of thrombus formation at any given set of experimental conditions. AUC was calculated for each independent experiment to determine the lowest dose at which thrombus formation was initiated using the standard quality control protocols at SomaLogic. All samples passed the established quality control criteria. P values were determined by t test.
Tail bleed assay. Mice were anesthetized with a ketamine (125 mg/kg) and xylazine (12.5 mg/kg) mixture in sterile saline via i.p. injection prior to a surgical dissection of the tail (5 mm from tip). Amputated tails were immediately immersed in 50 ml buffered saline prewarmed to 37°C and the time to bleeding cessation was recorded within 10 minutes (including start and stop time). The number of times bleeding stopped and re-started within the 10-minute observation window were recorded and categorized into bins as follows: 0 events, 1–3 rebleed events, or 4 or more events.

Endothelial cell culture. HUVEC (passage 1–5, pooled donors obtained from Lonza) monolayers cultured in EGM-2 media (Lonza) on gelatin- or collagen-coated culture vessels were treated with a cocktail of LPS (100 ng/ml), LPS-binding protein (LBP; R&D Systems; 10 ng/ml), and scCD14 (R&D Systems; 100 ng/ml) or vehicle (scCD14 and LBP) for 3 hours at 37°C. Pre- and postincubation with rAngpt-1 (R&D Systems; 200 ng/ml) or inhibitors was performed at indicated concentrations and time periods. A stable Ea.hy926 cell line expressing TF (Ea.hy629-TF) was made by transfecting Ea.hy926 cells with PLX304 vector expressing the F3 gene (NM_001993.4, clone HsCD00413770) using Lipofectamine 2000 (Life Technologies) and selecting positive colonies with blasticidin (6 μg/ml). A cell line with empty pLX304 vector was used as a control. Ea.hy926 cells were cultured in DMEM with 10% FBS and 5 μg/ml blasticidin.

siRNA transfection. HUVECs grown to 60%-70% confluence were transfected with Silencer Select (Thermo Fisher Scientific) negative control siRNA or a validated TEK (Tie-2) siRNA (s13984) using HiPerfect transfection reagent (Qiagen). A Cells-to-Ct 1-Step Taqman kit (Ambion/Life Technologies) and Taqm gene expression assay probe (Hs00945155-m1 TEK) were used to confirm reduction of gene expression following 48 hours of transfection. Quantitative reverse transcription PCR (qRT-PCR) was performed according to the manufacturer’s instructions (Thermo Fisher Scientific) at the BIDMC Molecular Medicine core.

Thrombin and Xa generation assays. Confluent HUVECs grown in 96-well plates were incubated with vehicle or LPS. For thrombin generation experiments, wells with confluent HUVECs (treated as above in “Endothelial cell culture”) were incubated with a mixture composed of 80 μl pooled human plasma (4 or 5 donors) to supply coagulation factors, the fibrin polymerization inhibitor H-Gly-Pro-Arg-Pro-OH (GPRP, 5 mM), 20 μl HEPES-buffered saline, pH 7.4 (HBS) and 1.5 to 5 mM CaCl₂. Thrombin levels were measured using the SN-2 fluorogenic substrate (Haematologic Technologies). Fluorescence was measured every minute for 20 minutes using the Synergy 4 plate reader (BioTek). Thrombin and Xa levels were determined using a fluorometric assay (Sigma-Aldrich) and phosphor-Akt (Ser473, 9271, Cell Signaling Technology), Akt (9272, Cell Signaling Technology), sheep anti-TF (Haematologic Technologies), an in-house anti-fibrin antibody made in a 59D8 hybridoma cell line, and anti-GAPDH (Cell Signaling Technology) or pan cadherin (AB6529, Abcam). Immunoblots were developed with SuperSignal West Pico/Femto Chemiluminescent Substrate (Thermo Fisher Scientific), and visualized with Syngene BioImage and GeneSnap image acquisition software. Protein phosphorylation levels were determined relative to the intensity of total protein level using antibodies from the same vendor.

Statistics. Statistical calculations were performed with GraphPad Prism version 6.0. Sample size determination was based on the expected effect size and variability from previous observations of similar readouts in the investigators’ labs. Statistical significance for binary comparisons was assessed by Student’s t test, unless the data did not pass the Shapiro-Wilk test for normality in which case differences between groups were analyzed by Mann-Whitney U test. For comparison of more than 2 groups, 1-way ANOVAs were used, according to the experimental design, with Bonferroni’s multiple comparison test. P values of less than 0.05 were considered statistically significant and marked by asterisks. For the clinical cohort, SAS Version 9.3 was used to perform statistical analyses. The degree of gene expression following 48 hours of transfection. Quantitative reverse transcription PCR (qRT-PCR) was performed according to the manufacturer’s instructions (Thermo Fisher Scientific) at the BIDMC Molecular Medicine core.

Preparation of protein lysates and Western blotting analysis. HUVECs and tissue lysate (40 μg) protein suspensions extracted with RIPA buffer (Boston BioProducts) supplemented with protease and phosphatase inhibitor tablets (Roche Diagnostics), 1 mM EDTA, 1 mM NaVO₄, and 1 mM NaF were resolved by SDS-PAGE (4%-12% gradient gel, Invitrogen) under reducing conditions (NuPage SDS sample buffer containing β-mercaptoethanol). After transfer to a nitrocellulose membrane, targeted protein detection was accomplished using the following antibodies: polyclonal rabbit anti-phospho-Tie2/TEK (epitope to protein kinase domain, Tyr992, ABF131; Millipore) and monoclonal mouse anti-Tie2/TEK (clone Ab63; Millipore), Human/Mouse Phospho-Tie-2 (Tyr992, AF2720, R&D Systems), and goat anti–mouse/rat Tie2 (AF762, R&D Systems), phosphor-Akt (Ser473, 9271, Cell Signaling Technology), Akt (9272, Cell Signaling Technology), sheep anti-TF (Haematologic Technologies), an in-house anti-fibrin antibody made in a 59D8 hybridoma cell line, and anti-GAPDH (Cell Signaling Technology) or pan cadherin (AB6529, Abcam). Immunoblots were developed with SuperSignal West Pico/Femto Chemiluminescent Substrate (Thermo Fisher Scientific), and visualized with Syngene BioImage and GeneSnap image acquisition software. Protein phosphorylation levels were determined relative to the intensity of total protein level using antibodies from the same vendor.
of diagnostic accuracy was determined by calculating the AUC with 95% confidence intervals. Unless otherwise indicated, data are represented as the mean ± SEM.

Study approvals. Samples for SOMAScan analysis were collected from the Molecular Epidemiology of ARDS (MEARDS) prospective cohort study (ClinicalTrials.gov Identifier: NCT00006496), which recruited patients at the ICUs of MGH and BIDMC between 1998 and 2014. The study was reviewed and approved by IRBs of Harvard School of Public Health, MGH, and BIDMC. All participants or their surrogate care providers gave written informed consent. A secondary analysis of patients who participated in 2 published studies was undertaken: (a) the Protocolized Care for Early Septic Shock (ProCESS) trial, a patient-level randomized, multicenter interventional trial of alternative resuscitation strategies in Emergency Department Sepsis (ClinicalTrials.gov Identifier: NCT00793442) (39); and (b) an IRB-approved prospective cohort study of 221 adult patients age 18 years and older presenting to the Emergency Department of BIDMC with suspected infection (27). Ethics committee approval was received from participating sites: the University of Pittsburgh and the BIDMC Committee for Clinical Investigations. Mouse care and experimental procedures were performed in accordance with and under the approval of the BIDMC Institutional Animal Care and Use Committee.

Author contributions
SJH and KDC designed, conducted, and analyzed experiments. SAC, XC, SS, and SL conducted experiments. XG, JAK, TAL, NIS, and DCC designed, conducted, and analyzed human subjects studies. The manuscript was written by SJH, KDC, RF, and SMP with input from all authors.

Acknowledgments
We are grateful to S. Ananth Karumanchi for critical discussion, to Glenn Merrill-Skoff for assistance with the microscopy, and to the ProCESS investigators for their contribution to subject enrollment and sample acquisition. This work was supported by the American Heart Association (grant 16POST31200017 to S.J. Higgins) and the NIH (T32HL007917 to K. De Cunynck, R01HL091757 to J.A. Kel-lum and N.I. Shapiro, P50GM076659 to J.A. Kellum and N.I. Shapiro, R35HL135775 to R. Flaumenhaft, R01HL093234/R35HL139424 to S.M. Parikh, and R01HL125275 to R. Flaumenhaft and S.M. Parikh).

Address correspondence to: Samir M. Parikh or Robert Flaumenhaft, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215, USA. Phone: 617.667.8000; Email: sparikh1@bidmc.harvard.edu (S.M. Parikh); rflaumen@bidmc.harvard.edu (R. Flaumenhaft).

The Journal of Clinical Investigation

